Recommendations for Transitioning and Combinations of Medications in Moderate to Severe Psoriasis

Patients with moderate-to-severe psoriasis frequently have to convert from a traditional systemic agent (methotrexate, acitretin, cyclosporine) to a biologic agent (etanercept, adalimumab, infliximab, ustekinumab), or change from one biologic agent to another, to achieve optimal control of their disease. At this point, evidence from the literature on how to do so is fragmentary. To make recommendations on this important issue, dermatologists from 33 countries contributed to a consensus report focused on treatment optimization and transition in the management of moderate-to-severe plaque psoriasis.

The participants addressed 14 relevant questions and achieved consensus on all. Published evidence was available for seven topics; expert opinion …